Weight-loss jabs for obese kids 'are effective and help prevent mealtime rows'
Weight-loss jabs for obese children are effective and help prevent battles around mealtimes, researchers have claimed.
Experts presented the findings at the European Congress on Obesity in Malaga, Spain.
They found that the drugs helped obese youngsters lose weight on top of a diet and lifestyle plan.
Weight-loss jabs, also known as GLP-1 receptor agonists, work by reducing food cravings.
They are available on the NHS for adults with a high body mass index (BMI) or through private providers.
The National Institute for Health and Care Excellence (Nice) stopped its appraisal of semaglutide (Wegovy) for use in 12 to 17-year-olds after the manufacturer, Novo Nordisk, said it was unable to provide evidence for submission.
In certain instances where there is a proven clinical need, specialist paediatric clinics can prescribe weight-loss injections.
Dr Annika Janson, from Karolinska University Hospital in Sweden, presented the new research.
She said: "GLP-1 drugs are increasingly used to treat obesity in adults.
"They can also be used in children from the age of 12 and clinical trials have shown children lose 5-16% of their body weight after a year of treatment."
Alongside this, Dr Janson said the jabs had results "beyond obesity".
"The families reported reduced conflicts around food and improved capacity for other lifestyle adaptations," she said.
She added: "It was easier to stick to meals and limit snacks. Portions could be downsized. For some children, not being hungry all the time is a new feeling."
Side effects of weight-loss drugs include nausea, diarrhoea, stomach cramps and vision problems.
A spokesperson for Novo Nordisk said the company hadn't submitted evidence for Nice appraisal because it lacked "utility data and risk equations in linking weight loss in adolescents to long-term outcomes."
It added that, at this time, it had no intention of making an evidence submission.
Last year, said that children in the UK were getting shorter, fatter and sicker due to "shocking levels" of poverty and food deprivation.
It found that among 10 to 11-year-olds had increased by 30% since 2006, with one in five children classed as obese by the time they leave primary school.
It comes as new data presented by Novo Nordisk showed that Wegovy for adults could help protect against heart disease in the earliest stages.
Read more from Sky News:
Alongside this, it was said to cut the risk of heart attack, stroke or early death in high-risk patients.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Hims & Hers Stock Is Soaring Again. But Should You Buy the Stock?
Hims & Hers stock is on the upswing after the company secured a weight-loss drug partnership. Hims & Hers is acquiring its way into Europe and wants to build more personalized drugs for its telehealth customers. Shares have soared, but still have a ton of potential for patient long-term shareholders. 10 stocks we like better than Hims & Hers Health › Many companies have failed to disrupt the complicated U.S. healthcare market. Hims & Hers (NYSE: HIMS) may finally be succeeding in cracking the code. The online telehealth platform focuses on circumventing the insurance market; its business of selling affordable medications directly to individuals is growing like a weed, and expects to generate $6.5 billion in revenue by 2030. It has had a tumultuous start to 2025, as Hims & Hers waged a battle to sell new weight loss medications on its online marketplace. Now, with momentum back on its side, the stock is up 118% year to date and 446% in the last five years. Let's take a deeper look at this company, and see whether you might want to buy Hims & Hers stock for your portfolio now. Hims & Hers' model is simple. It has two separate web platforms -- Hims for men and Hers for women -- that sell medications and deliver to customers' front doors. It began with sexual health, but has moved into dermatology, hair loss, mental health, and now weight loss medications. A key to its success has been avoiding the insurance market with products that don't break the bank. Customers loathe dealing with health insurers in the United States, and sometimes would rather not use insurance at all. Plus, some of these products aren't covered by insurance. This strategy has helped the company close in on over $2 billion in projected revenue in 2025. To keep up this impressive growth, Hims & Hers wants to offer weight loss medications, which have been a blockbuster set of drugs for the pharmaceutical market. For a while the popularity of these drugs, such as Novo Nordisk's Wegovy, left them in short supply; that allowed third parties such as Hims & Hers to produce them as a compounding pharmacy and sell them at much cheaper prices. This ended up generating $200 million of Hims & Hers' $1.4 billion in 2024 revenue. But with the shortage of Wegovy over and the compounding pharmacy exception ended, the company's weight-loss business was at a major turning point. Luckily, at the end of April Hims & Hers announced a partnership with Novo Nordisk that seems to resolve this issue: It gives Hims & Hers the ability to sell Wegovy directly on its platform. Hims & Hers is not an exclusive supplier of the drug -- or any drugs on its marketplaces, to be fair -- but it hopes to use its subscription business model, marketing expertise, and simplified user proposition to drive sales for Novo Nordisk in the huge obesity-care market. Besides weight loss drugs, Hims & Hers has more ambitions to reach its goal of $6.5 billion in revenue by 2030. Just recently, the company announced its intent to acquire European competitor Zava so it could expand its telehealth service to Europe. The acquisition will add a platform with 1.3 million active customers in the U.K., Germany, France, and Ireland. It makes sense that Hims & Hers can supercharge growth for the platform with its plethora of medications offered to customers, keen marketing skills, and subscription-based selling model. Over the long run, Hims & Hers aims to make healthcare for its customers more personalized. This includes unique drug combinations, its own outsourcing facility, and at-home testing capabilities. Details remain sparse, but the vision is clear: disrupting more and more of the trillions of dollars spent on healthcare by building a business that people actually enjoy interacting with. This is why 2.4 million active customers use Hims & Hers today. A revenue goal of $6.5 billion seems well within reach by 2030. Hims & Hers is only at 2.4 million active customers, and there are tens of millions of people in the United States alone who could start using or switch to one of its telehealth platforms. Add on the Zava acquisition in Europe, and the runway for growth gets even larger. The company has an impressive gross profit margin of 77%, which should lead to high levels of profitability at scale. On $6.5 billion in future revenue, it could very well post a net profit margin of over 20%, and achieve $1.5 billion in bottom-line profits and free cash flow. A 20% profit margin is easily achievable because of its high gross margins and the fact it currently spends 40% of revenue on marketing today, a figure that has come down over time and should come down even more as Hims & Hers keeps scaling. However, Hims & Hers has played fast and loose with laws and regulations in the past. It sold weight loss drugs when the legality of doing so was unclear, and although that dispute seems to have been resolved, management could easily start playing with fire again and burn its reputation as a trusted provider of medications. Otherwise, this looks like a fantastic growth stock that just doubled its addressable market with the Zava acquisition. Today, Hims & Hers has a market cap of $12.3 billion. You might think it's overvalued because of the stock's recent run-up in price, but the numbers show that patient investors could be rewarded by holding for the long term. A $12.3 billion market cap is only around 8 times my 2030 earnings estimate of $1.5 billion, which would be a dirt cheap price-to-earnings (P/E) ratio for a fast-growing company compared to the current market cap. Most likely, the stock will be valued at a higher multiple than 8, meaning that the stock will be higher in five years. It doesn't come without risks, but if you're a growth investor, you might love Hims & Hers stock for its long-term potential. Before you buy stock in Hims & Hers Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Hims & Hers Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Brett Schafer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Hims & Hers Stock Is Soaring Again. But Should You Buy the Stock? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
NHS spends £1.8bn a year on private firms, says GMB in call to end outsourcing
A trade union is stepping up calls to end privatisation in the NHS after its research suggested health trusts spend at least £1.8 billion a year on private companies. The GMB said requests using freedom of information laws to more than 200 trusts show they spend £1,831,105,580 annually on outsourced contracts. Almost half the trusts did not respond so the true figure could be far higher, it is claimed. A separate investigation found ambulance trusts across England spent £290 million on private ambulances during the past three years. The total annual spend has almost doubled since 2021/22, according to the data. The GMB said it wants to send a message to the Government from its annual congress in Brighton on Monday. Ambulance worker Mo Akbar will tell delegates: 'GMB members demand an end to privatisation. 'We must bring all outsourced services like cleaning, catering, and facilities back in-house. 'We demand real-terms restorative pay from the 14 years of brutal austerity. 'Workers and communities should have more say in how the NHS is run, ensuring decisions focus on patient care, not financial targets. Health outcomes are tied to poverty, housing, and working conditions, so NHS rebuilding must also address these inequalities. 'This Labour Government will have a crisis of legitimacy if they choose a path of further privatisation of the NHS, which would put at risk the sense of the collectivism that is at the heart of our health service 'We must be resolute in fighting for our National Health Service.'
Yahoo
2 hours ago
- Yahoo
Nurses to vote on pay deal amid concerns of industrial action
Nursing staff will start voting today on the Government's 3.6% pay deal amid warnings of another industrial dispute involving strikes. Around 345,000 members of the Royal College of Nursing (RCN) will be asked if the pay award is enough in what was described as the biggest single vote of the profession ever launched in the UK. Last month, the Westminster government accepted the recommendation of the Pay Review Body, giving nursing staff In England's NHS a pay rise of 3.6%. The RCN described the award as 'grotesque', saying it will see nursing staff receive a pay rise 'entirely swallowed up by inflation' – with doctors, teachers, prison officers and the armed forces all receiving a bigger increase. An identical award was made in Wales, while in Northern Ireland, the Health Minister has announced his wish to implement a 3.6% pay rise, but this is still to be agreed. The RCN said the vote will be crucial in determining the next steps, which could include a ballot for strike action. The vote will include RCN members working in the NHS in England, Wales and Northern Ireland. Speaking from an international nursing conference in Helsinki and on the launch of the vote, Professor Nicola Ranger, RCN general secretary, will say: 'I'm with nurses from around the world today asking why it is our ministers in the UK who have once again put nursing at the back of the queue when it comes to pay. 'Nursing is an incredible career, but despite being the most valued profession by the public we continue to be weighted to the bottom of the NHS pay scale and are set to receive one of the lowest pay awards. 'It is time to show that nurses are valued and, from today, hundreds of thousands of nursing staff working in the NHS will give their verdict on whether 3.6% is enough.' The RCN said nursing staff in England have faced more than a decade of pay erosion since 2010/11, with pay down by a quarter in real terms. As a result, there are more than 26,000 unfilled nursing posts, while student recruitment has 'collapsed' and the numbers quitting is 'skyrocketing', said the RCN. Professor Ranger will add: 'Over a decade of pay erosion has had a devastating impact on our profession, forcing increasing numbers into quitting while putting off the nurses of the future. 'When our members vote, they won't just be voting on the fairness of the award for themselves, but if it's enough to turn our profession around.' NHS workers including nurses staged a series of strikes under the previous Conservative government in bitter disputes over pay.
